Skip to content

Author

Gavin B. Chapman

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Jun 2026

Endothelin antagonism: a new era for resistant hypertension

In the phase 3 PRECISION trial, aprocitentan significantly reduced blood pressure in patients with resistant hypertension, with additional reductions in albuminuria, and may provide benefits beyond blood pressure reduction.

G. Chapman, D. Pugh, N. Dhaun · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.